🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareCost-effectiveness analysis: GLP-1 agonists vs bariatric surgery (ICER 2026) — looking for input Page 3

Cost-effectiveness analysis: GLP-1 agonists vs bariatric surgery (ICER 2026) — looking for input

SkepticalSean Sat, Sep 27, 2025 at 2:23 AM 14 replies 1,388 viewsPage 3 of 3
KristenIndy
Member
623
2,678
May 2024
Indianapolis, IN
Sep 27, 2025 at 6:38 AM#11
Dr.BariatricHTX said:
Cost-effectiveness analysis GLP-1 is not that straightforward in my experience

This is exactly right. Dr.BariatricHTX articulated what I have been trying to explain to my doctor for months. The Cost-effectiveness aspect is the most important factor.

Last edited: Sep 27, 2025 at 11:38 AM
46 10LondonLisa, mike_nyc, VendorMark and 43 others
Reply Quote Save Share Report
tane_welly
Member
234
1,123
Sep 2024
Wellington, NZ
Sep 27, 2025 at 6:55 AM#12

Reading this thread on Cost-effectiveness hits close to home. Night shift nurse — I started at 299 lbs and felt like I would tried everything.

15 months on tirz and I am a different person. Not just the 74 lbs lost — my energy, my mood, my relationship with food. All transformed.

If you are on the fence about Cost-effectiveness — take the leap. It was the best health decision I have ever made. ❤️

37 1carl_compliance, DanielChem_CHI, marco_milano and 34 others
Reply Quote Save Share Report
FranDenver
Member
267
1,123
Oct 2024
Denver, CO
Sep 27, 2025 at 7:12 AM#13

Dr.EM_Chicago — that is really helpful context on Cost-effectiveness. Follow-up question: what labs did your doctor order to monitor this?

I am in a similar situation (just started) and trying to set realistic expectations.

Last edited: Sep 27, 2025 at 1:12 PM
22 0BariatricNurseD, MASHdoc_SA, GenomicsKate and 19 others
Reply Quote Save Share Report
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Sep 27, 2025 at 7:29 AM#14

To answer tane_welly's question specifically:

From a clinical standpoint, Cost-effectiveness analysis is an area where we have good evidence.

The short answer: baseline labs + quarterly monitoring is the standard of care.

The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.

4 21tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 1 other
Reply Quote Save Share Report
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Sep 27, 2025 at 7:46 AM#15

Bookmarked 📌 The Cost-effectiveness info in this thread is essential. Coming back to this for sure.

Last edited: Sep 27, 2025 at 9:46 AM
17 7Dr.ObesityLA, NurseKim_ATL, paul_denver and 14 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register